Floatz logo

11 assets in Skin Basal Cell Carcinoma

Therapeutic assets addressing Skin Basal Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Nivolumab
Skin Basal Cell Carcinoma
Fred Hutchinson Cancer CenterP2B (63)
L19IL2/L19TNF
Skin Basal Cell Carcinoma
Philogen S.p.A.P2CCC (53)
Ipilimumab
Skin Basal Cell Carcinoma
National Cancer Institute (NCI)P1/2CCC (52)
Prednisone
Skin Basal Cell Carcinoma
National Cancer Institute (NCI)P1/2CCC (52)
Sirolimus
Skin Basal Cell Carcinoma
National Cancer Institute (NCI)P1/2CC (47)
mq719
Skin Basal Cell Carcinoma
Memorial Sloan Kettering Cancer CenterP1CC (43)
Pembrolizumab
Skin Basal Cell Carcinoma
Memorial Sloan Kettering Cancer CenterP1CC (43)
Tacrolimus
Skin Basal Cell Carcinoma
National Cancer Institute (NCI)P1CC (43)
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE
Skin Basal Cell Carcinoma
National Cancer Institute (NCI)P2NR ()
Ivocizumab
Skin Basal Cell Carcinoma
Fudan UniversityP2NR ()
Kup-101A
Skin Basal Cell Carcinoma
Kupando GmbHP1NR ()